Update on Campylobacter jejuni vaccine development for preventing human campylobacteriosis.
Campylobacteriosis constitutes a serious medical and socioeconomic problem worldwide. Rapidly increasing antibiotic resistance of bacterial strains compels us to develop alternative therapeutic strategies and to search for efficient immunoprophylactic methods. The vast majority of Campylobacter infections in developed countries occur as sporadic cases, mainly caused by eating undercooked Campylobacter-contaminated poultry. The most efficient strategy of decreasing the number of human Campylobacter infections is by implementing protective vaccinations for humans and/or chickens. Despite more than 10 years of research, an effective anti-Campylobacter vaccine has not been developed. This review highlights our increasing knowledge of Campylobacter interaction with host cells and focuses on recently published data describing the efficacy of anti-Campylobacter vaccine prototypes.
Jagusztyn-Krynicka
Elzbieta Katarzyna
EK
Department of Bacterial Genetics, Institute of Microbiology, Faculty of Biology, University of Warsaw, Warsaw, Poland. kjkryn@biol.uw.edu.pl
Łaniewski
Paweł
P
Wyszyńska
Agnieszka
A
D000818:Animals; D001428:Bacterial Vaccines / Q000276:immunology*; D002169:Campylobacter Infections / Q000453:epidemiology / Q000517:prevention & control*; D016123:Campylobacter jejuni / Q000276:immunology*; D019049:Developed Countries; D006801:Humans; D008461:Meat Products / Q000382:microbiology; D011200:Poultry / Q000382:microbiology
D001428:Bacterial Vaccines